CD6 is a target for cancer immunotherapy

Jeffrey H. Ruth, … , Feng Lin, David A Fox


Graphical abstract

Find the latest version:

https://jci.me/145662/pdf
CD6 is a Target for Cancer Immunotherapy

Jeffrey H. Ruth\textsuperscript{1*}, Mikel Gurrea-Rubio\textsuperscript{1*}, Kalana S. Athukorala\textsuperscript{1}, Stephanie M. Rasmussen\textsuperscript{1}, Daniel P. Weber\textsuperscript{1}, Peggy Randon\textsuperscript{1}, Rosemary J. Gedert\textsuperscript{1}, Matthew E. Lind\textsuperscript{1}, M. Asif Amin\textsuperscript{1}, Phillip L. Campbell\textsuperscript{1}, Pei-Suen Tsou\textsuperscript{1}, Yang Mao-Draayer\textsuperscript{2}, Qi Wu\textsuperscript{2}, Thomas M. Lanigan\textsuperscript{1}, Venkateshwar G. Keshamouni\textsuperscript{3}, Nora G. Singer\textsuperscript{4,5}, Feng Lin\textsuperscript{6}, David A. Fox\textsuperscript{1}

\textsuperscript{1}Division of Rheumatology, \textsuperscript{2}Department of Neurology and \textsuperscript{3}Division of Pulmonary & Critical Medicine, University of Michigan, Ann Arbor, MI. \textsuperscript{4}Case Western Reserve University, \textsuperscript{5}Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH; \textsuperscript{6}Department of Immunity and Inflammation, Lerner Research institute, Cleveland Clinic, Cleveland, OH

*these authors contributed equally to this study

Correspondence to: Jeffrey H. Ruth, PhD
University of Michigan Medical School
Department of Medicine, Division of Rheumatology
Email: jhruth@umich.edu

and

David A. Fox, MD
University of Michigan Medical School
Department of Medicine, Division of Rheumatology
Email: dfox@med.umich.edu

Conflicts of interest: none

Keywords: CD6, CD318, immune checkpoint, cancer

Running title: Inhibition of lymphocyte CD6 reduces cancer progression
Abstract

Limitations of checkpoint inhibitor cancer immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Since CD318, a novel CD6 ligand, is associated with aggressiveness and metastatic potential of human cancers, we tested the effect of an anti-CD6 monoclonal antibody, UMCD6, on killing of cancer cells by human lymphocytes. UMCD6 augmented killing of breast, lung or prostate cancer cells through direct effects on both CD8+ T cells and natural killer (NK) cells, increasing cancer cell death and lowering cancer cell survival in vitro more robustly than monoclonal antibody checkpoint inhibitors that interrupt the PD-1/PD-L1 axis. UMCD6 also augmented in vivo killing by human peripheral blood lymphocytes of a human breast cancer line xeno-transplanted into immunodeficient mice. Mechanistically, UMCD6 upregulated the expression of the activating receptor NKG2D and down-regulated expression of the inhibitory receptor NKG2A on both NK cells and CD8+ T cells, with concurrent increases in perforin and granzyme-B production. The combined capabilities of an anti-CD6 monoclonal antibody to control autoimmunity through effects on CD4+ lymphocyte differentiation, while enhancing killing of cancer cells through distinct effects on CD8+ and NK cells, opens a potential new approach to cancer immunotherapy that would suppress rather than instigate autoimmunity.
Introduction

Checkpoint inhibitor therapy, directed at PD-1, PD-L1 or CTLA4, has revolutionized cancer immunotherapy. However, cancers respond with varying efficacy to checkpoint inhibition, and many patients also experience severe autoimmune-related adverse events with these therapies. Therefore, additional targets are needed on cancer cells and lymphocytes that enhance immune cell elimination of tumors without engendering autoimmune toxicities through inducing lymphocyte self-reactivity. CD318 (CDCP1, TRASK, SIMA135, or gp140) is a cell surface glycoprotein that is widely expressed by cancer cells, and its degree of expression correlates with cancer aggressiveness and metastatic potential (2-4). Prior studies of CD318 have been limited to its intrinsic roles in cancer cell biology, but its possible participation in immune regulation has not been examined. Notably, we recently discovered that CD318 is a second ligand for the CD6 T cell surface glycoprotein (5).

CD6 is a 105-130 kDa type I transmembrane glycoprotein belonging to the highly conserved scavenger receptor cysteine-rich superfamily (SRCR-SF) (6), almost exclusively expressed by lymphocytes, including most mature T cells and about 50% of NK cells (7). CD6 is also a receptor for CD166/ALCAM (Activated Leukocyte Cell Adhesion Molecule) (8,9). The interaction between CD6 and CD166 helps to stabilize the adhesive contacts established between T cells and antigen-presenting cells (APCs) as well as to optimize subsequent proliferative and differentiation responses (10-12).

We recently showed CD6 to be essential in murine models of multiple sclerosis (MS) (13), uveitis (14), and rheumatoid arthritis (RA) (15). In both CD6-/- mice and CD6-humanized mice treated with UMCD6, a mouse anti-human CD6 monoclonal antibody (mAb), striking reductions in clinical signs of disease, pathogenic Th1/Th17 responses and inflammatory cell infiltration into the target organs were observed (13-15). Both known CD6 ligands, CD318 and CD166, participate in adhesion of T cells to fibroblast-like synoviocytes (FLS) derived from RA synovial tissue by engagement of distinct domains on CD6. Moreover, soluble CD318 (sCD318) is found...
in RA synovial fluid at levels higher than in normal or RA serum, and sCD318 is chemotactic for T cells at a concentration equal to this *in vivo* gradient (5).

In light of these recent observations, we have now tested the effects of interrupting the interactions between CD6 on lymphocytes with CD6 ligands on cancer cells on the ability of human lymphocytes to kill the cancer cells. Co-culture experiments using a multiplexed time-lapsed imaging system, including cell lines derived from human triple-negative breast cancer, non-small-cell lung cancer and prostate cancer, showed substantial enhancement of cancer cell death and reduced survival of cancer cells in the presence of UMCD6 and otherwise non-stimulated human lymphocytes. This effect was consistently more robust *in vitro* than the effect of either pembrolizumab or nivolumab, which are checkpoint inhibitor immunotherapies that are currently widely used in cancer treatment. We also demonstrate that augmentation of lymphocyte cytotoxicity by UMCD6 is due to direct effects of this mAb on natural killer (NK) cells and CD8+ cytotoxic T cells, including augmentation of the expression of the activating receptor NKG2D and decreased expression of the inhibitory NKG2A receptor. Moreover, UMCD6 exerted similar effects *in vivo* in a human breast cancer xenograft system in immunodeficient mice. Both *in vitro* and *in vivo*, UMCD6 is rapidly internalized and is therefore a non-depleting mAb.

These results indicate that CD6 is a promising new target for cancer immunotherapy. Because anti-CD6 has distinct effects on CD4+ cells to suppress autoimmunity, coupled with direct effects on CD8+ cells and NK cells that promote the killing of cancer cells, use of this approach to treat human cancer could avoid the troubling autoimmune complications frequently seen with currently available checkpoint inhibitors.
Results

High expression of CD318 on cancer cell lines. Multiple human cancer cell lines were analyzed by flow cytometry for expression of CD318, which was recently described as a second ligand of CD6 (figure 1). The majority of malignant cell lines derived from patients with breast cancer, non-small cell lung cancer, prostate cancer and melanoma were all CD318+, several at very high mean fluorescence intensity. Breast cancer cell line MCF7 (S1) and melanoma cell line UM-MEL1 (data not shown) had little or no surface CD318. All lines tested expressed moderate to high levels of CD166/ALCAM, a ligand of CD6 that is found on activated leukocytes, cancer cells and many normal tissue cell populations (16). We confirmed the flow cytometry results by Western blot analysis of MDA-MB-231 (surface CD318+) and MCF7 (surface CD318-) breast cancer cells, and also tested the effect of IFN-γ which induces expression of CD318 on non-neoplastic cells such as synovial fibroblasts. Abundant CD318 was present in lysates of MDA-MB-231 compared to a lesser amount in MCF7 lysates, and IFN-γ did not alter expression of CD318 by these cells (figure 1 and S1) or by other cancer cell lines (data not shown). Soluble CD318 was shed into the culture medium from the surface of CD318+ breast cancer cells (figure 1), as previously observed in cultures of RA synovial fibroblasts, and at concentrations shown to induce T cell chemotaxis (5). Moreover, T lymphocytes adhered in greater numbers to a CD318+ than a surface CD318-negative breast cancer line (lower right panel - figure 1).

In vitro killing of breast and prostate cancer cells is enhanced by monoclonal antibodies to CD6 or CD318. To explore the possibility that CD6-CD318 could be a potential target for lymphocyte checkpoint inhibition, we used an IncuCyte imaging device, to image co-cultures of cancer cell lines and PBMCs or purified lymphocyte subsets, with or without anti-CD6 (UMCD6) or anti-CD318 (3a11) mAbs. As controls, we used mAb to LFA-1/CD11a/CD18, an isotype-matched anti-von Willebrand Factor (vWF) mAb that does not bind to lymphocytes or cancer cells, and/or
mouse IgG. Additionally, a non-toxic caspase reagent, that fluorescently labels dying cells, was added to proliferating cancer cells without the addition of immune cells or antibody, to monitor cancer cell growth and survival in culture.

We investigated whether blocking CD6 or CD318 would affect immune cell mediated killing of multiple cancer cell lines and overall growth/survival of the cultured cancer cells. Pre-incubation of cancer cells with mAb 3a11 (mouse anti-human CD318) enhanced killing and inhibited survival of cancer cells compared to the control antibodies (anti-vWF and anti-LFA-1), but UMCD6 (anti-CD6) was more effective than anti-CD318 in augmenting cancer cell killing by PBMCs (figure 2, top panels). Interpretation of the effects of anti-CD318 could be confounded by the potential for non-specific triggering of antibody-dependent cellular cytotoxicity through opsonization of cancer cells by anti-CD318, in addition to interruption of the ability of CD318 to engage CD6. Moreover, CD318 might not be a suitable molecular target for in vivo immunotherapy, due to its expression on many types of stromal and epithelial cells. Therefore, subsequent experiments focused primarily on UMCD6 and not anti-CD318.

Similar robust induction of breast cancer cell death and overall decrease in the number of surviving cancer cells was observed with UMCD6, using PBMCs from a second donor (figure 2, middle panels) and in PBMC co-culture with a prostate cancer line (figure 2, lower panels). Cancer cell cultures with caspase reagent only (no antibodies or PBMCs added) showed insignificant cancer cell death and rapid cancer cell proliferation (figures 2 and S2).

**UMCD6 effectively mediates PBMC killing of non-small-cell lung carcinoma (NSCLC) and breast cancer cells compared to pembrolizumab and nivolumab in vitro.** We next evaluated the effectiveness of UMCD6 in enhancing killing of cancer cells representative of a cancer type, NSCLC, in which PD-1/PD-L1 targeted checkpoint inhibitor immunotherapy is currently widely used. In these experiments we compared the effects of UMCD6 with pembrolizumab and nivolumab, agents that target the PD1-PDL1 checkpoint pathway. Freshly isolated human PBMCs
were pre-incubated with either UMCD6, pembrolizumab, nivolumab or an anti-vWF control antibody. After an hour pre-incubation, treated PBMCs were added to NCI-H460 tumor cells with a caspase detection reagent and monitored for cellular caspase expression (indication of immune cell killing) and tumor cell growth and survival, by the number of fluorescing red tumor cells remaining in co-culture over time (figure 3 – upper panel). As observed with the breast and prostate cancer cell lines, a substantial increase in NCI-H460 cell death occurred in the UMCD6 treated compared to the anti-vWF treated co-cultures. Moreover, the effects of UMCD6 on cancer cell death and survival were significantly stronger than the effects of either pembrolizumab and nivolumab, when used at identical concentrations (figures 3 and S3). Thus, PBMCs pre-treated with UMCD6 enhanced caspase expression and inhibited NSCLC cell survival far better than checkpoint inhibitor immunotherapeutics currently used in clinical care. However, experimental conditions were not designed to optimize expression of PD-1.

Results from a multivariate survival analysis in patients with lung adenocarcinoma stratified according to cancer cell expression of the CD6 ligands CD318 and CD166/ALCAM, using two different Affymetrix probes, showed that increased expression of CD318 correlates strongly with poor survival in patients with lung adenocarcinoma (n=387) (figure 3 lower panels), consistent with previous observations (17). Conversely, lung adenocarcinoma expression of CD166/ALCAM correlates with an improved prognosis (figure 3 lower panels). These results suggest that CD6 interactions with CD6 ligands that are expressed on cancer cells have an important influence on clinical outcomes of cancer patients and point to the CD6/CD6 ligand axis as a potential new therapeutic target in cancer treatment.

Superiority of UMCD6 in stimulating cancer cell killing by PBMCs was not confined to lung cancer but was also readily demonstrated using a breast cancer line (figure 4). Images of photomicrographs at 4 time points during a real-time kinetic immune cell cancer killing assay from the IncuCyte system show caspase expression by HBCCs (fluorescent green) in co-culture with PBMCs pre-incubated with UMCD6, as early as 30 hours - which increases significantly at 61
hours and beyond (figure 4 – lower panel). There is a notable attrition of fluorescing red tumor cells in this co-culture at 61 hours through the end of the assay, effects that were less evident in co-cultures treated with pembrolizumab, nivolumab or control antibodies.

UMCD6 directly activates cytotoxic lymphocytes. Since both CD8+ T cells and a subset of human NK cells express CD6 (7,8), we next asked whether either or both of these populations could be activated by UMCD6 to manifest augmented killing of cancer cells. Indeed, UMCD6 enhanced cancer cell killing by purified human CD8+ or NK cells (figure 5). As expected, PBMCs treated with UMCD6 showed enhanced killing and reduced survival of breast cancer cells in co-culture. Pembrolizumab and nivolumab also showed enhanced PBMC mediated killing activity and reduced viability of the cancer cells, but to a lesser degree than what was observed with UMCD6 (figure 5 – upper panel). Similarly, UMCD6-treated CD8+ lymphocytes, isolated from PBMCs by negative selection, showed better killing with UMCD6 compared to pembrolizumab or nivolumab (figure 5 – middle panel). Notably, purified CD56+ NK cells showed distinct and robust effects on cancer cell killing and survival curves that were seen only in the presence of UMCD6 (figure 5 – lower panel). Neither pembrolizumab nor nivolumab had any effect on NK cell killing of cancer cells, possibly due to the low expression of PD-1 on non-activated NK cells. These results point to unique mechanisms of action of UMCD6 compared to other checkpoint inhibitors in activating lymphocyte subsets, especially NK cells.

Because activation of T cells by monoclonal antibodies such as anti-CD3 can be accompanied by internalization of their target surface structures (18), we asked whether UMCD6 induced internalization of CD6. Indeed, UCMD6 quickly led to capping of CD6 with subsequent clearing of CD6 from the cell membrane over six hours (figure S4). UMCD6-treated lymphocytes remained CD6-negative for several days, consistent with previous observations in vivo in CD6-humanized mice, in which a large population of CD6-negative lymphocytes appeared after administration of UMCD6 (15).
**UMCD6 enhances PBMC killing of human breast cancer cells in vivo.** To evaluate the therapeutic efficacy of UMCD6 in vivo, we next generated a xenograft mouse model of triple-negative breast cancer by subcutaneously injecting $5 \times 10^6$ luciferase-labeled MDA-MB-231 cells into the right flank region of immunodeficient SCID beige mice. Tumor proliferation was monitored by bioluminescence imaging. 26 days after tumor implantation, when tumors reached volumes of at least $100 \text{mm}^3$, 10 mice received an intravenous injection of $1.2 \times 10^7$ PBMCs via the tail vein, while the 3 other mice received PBS. The following day, mice that had received PBMCs were intraperitoneally injected with a single dose of UMCD6 or IgG control (400µg/mouse). As measured by bioluminescent imaging, tumor growth was significantly reduced in mice that received UMCD6 compared to control IgG at day 4 (*p=0.038) and day 7 (*p=0.0052) post antibody injection (figure 6 upper and middle panels).

Because soluble CD318 is chemotactic for T cells\(^5\), we investigated whether cytotoxic lymphocytes migrated to tumor sites. At 10 days after the injection of PBMCs, tumors were harvested and frozen sections were immunostained for tumor-infiltrating lymphocytes. Both CD3+ T cells and CD56+ NK cells were found exclusively in mice that had received an intravenous injection of PBMCs (figure S5). Although NK cells do not always infiltrate tumors, their presence in tumor biopsies has been positively associated with increased survival and better prognosis in several cancer types (19-23). Both T cells and NK cells appeared activated, and were more abundant in tumors from mice treated with UMCD6 than in IgG control mice. We also determined the tumor cell density in each tumor based on the number of mKate2 expressing cells. Treatment with UMCD6 reduced the number of remaining tumor cells per field compared to controls (figures S5 and S6). These in vivo results are fully consistent with the participation of both NK cells and T cells in the anti-tumor effects of UMCD6-stimulated lymphocytes in vivo, as seen in vitro.

**UMCD6 induces up-regulation of NKG2D on NK and CD8+T cells.** NK cell and CD8+ T cell functionality is regulated by a balance between a variety of activating and inhibitory receptors
including CD94/NKG2A (inhibitory) and CD314/NKG2D (activating). Once activated, NK cells and CD8+ T cells exhibit cytotoxicity and cytokine production against tumor cells and virus-infected cells. To investigate the mechanisms by which CD6+ human NK cells are stimulated by UMCD6 to kill neoplastic cells, we asked whether UMCD6 affected the expression of various activating and inhibitory receptors on a human NK-cytotoxic cell line (NK-92). Interestingly, NKG2A mRNA levels were reduced in UMCD6-treated NK-92 cells four hours after incubation with UMCD6, while NKG2D expression was up-regulated. A significant enhancement of perforin and granzyme-B expression was also observed upon activation with UMCD6, confirming that CD6 plays an important mechanistic role in NK cell activation (figure 7, upper panels).

In addition to NK-92 cells, PBMCs from six subjects were also used to study the influence of UMCD6 on expression levels of these four key molecules by both NK and CD8+ T cells. The patterns of alteration of expression of these molecules by UMCD6 were similar to the results seen with NK-92 cells (figure 7 and supplementary figure 7). Upon activation with UMCD6, NK cells upregulated expression of NKG2D by 48 and 72 hours, whereas downregulation of NKG2A was observed (*p<0.05). Granzyme-B expression was also upregulated by 48 hours (*p<0.05) and perforin expression was upregulated by 48 and 72 hours (p<0.05). UMCD6 also altered the expression levels of NKG2A, NKG2D, Granzyme-B and perforin by CD8+ T cells from 5 out of 6 healthy blood donors, similar to the results seen with NK cells from all 6 donors.

**Discussion**

The data in this report establish powerful stimulatory effects of an anti-CD6 monoclonal antibody, UMCD6, on the ability of human lymphocytes to kill cancer cells of multiple types. We observed direct effects of UMCD6 on the killing ability of purified CD8+ T cells and purified NK cells. In contrast to currently employed checkpoint inhibitor cancer immunotherapies such as pembrolizumab and nivolumab, CD4+ T cells are not required for this effect of UMCD6. However,
UMCD6 does have important effects on activation and differentiation of CD4+ cells that explain the beneficial effects of UMCD6 in animal models of human autoimmune diseases.

Both in CD6-/- mice and in CD6-humanized mice treated with anti-CD6, robust protective effects were seen in mouse models of multiple sclerosis (13), autoimmune uveitis (14) and RA (15). The therapeutic benefit was manifested by amelioration of clinical indicators of disease, attenuation of the immune cell infiltrates into the target organs and marked reduction of the Th1 and/or Th17 immune responses that are essential to these conditions. Initial stages of lymphocyte activation were not inhibited by genetic absence of CD6 or use of UMCD6 in the CD6-humanized mice, and these mice did not become lymphopenic when UMCD6 was administered (15). Lack of T cell depletion is attributable to the rapid internalization of CD6 upon binding of UMCD6 to the cell surface, and abundant CD3+/CD6- T cells were therefore detected *in vivo* after treatment with anti-CD6. Following internalization of CD6 by UMCD6, recovery of CD6 surface expression is delayed for at least several days. Therefore, the enhanced killing of cancer cells in our experiments occurs with CD8+ lymphocytes and NK cells that are CD6-negative and unable to bind either CD6 ligand displayed on the cancer cell surface.

The known cell surface ligands of CD6 are CD166/ALCAM and CD318, also known as CDCP1 or TRASK (5). Either or both ligands are widely expressed by human cancers (24,25), and we have not encountered a cancer cell line that lacks strong expression of at least one of these molecules. We previously observed that CD318 is shed from RA FLS and accumulates in a soluble form in RA synovial fluid at levels higher than found in normal or RA sera (5). At a concentration equal to this *in vivo* gradient, soluble CD318 is chemotactic for CD6+ lymphocytes. Like FLS, CD318+ cancer cells shed CD318 into their culture medium and are likely to also do this *in vivo*. For this reason, the *in vivo* breast cancer experiment was designed so that the infused human lymphocytes would have an opportunity to respond to soluble CD318 by migrating into the tumor microenvironment, and the injection of UMCD6 was therefore given one day later than the infusion of human PBMCs.
The heightened ability of UMCD6-treated CD6-negative lymphocytes to kill cancer cells implies that CD6 ligands on the cancer cells deliver a negative signal to CD8+ and NK cytotoxic lymphocytes. Whether both CD166 and CD318 are equally potent in this way is not known, but CD318 appears to be more broadly associated with a worse clinical outcome in human cancers (26-28). In non-small cell lung cancer for example, high expression of CD318 associates with poor outcome (29) while the opposite is true for CD166 (30). Experiments that manipulate the expression of these ligands on various cancer cell lines may be useful in addressing this issue. In autoimmune diseases, these ligands, which engage distinct domains of CD6, can have opposing effects. Thus, CD318-/- mice reproduced the phenotype of attenuated disease seen in CD6-/- mice in the mouse experimental autoimmune encephalomyelitis (EAE) model of MS (13), but mice lacking CD166 experienced exacerbation of EAE (31).

The hypothesis that cancer cell ligands of CD6 impair the function of cytotoxic lymphocytes is supported by experiments in which forced expression in vivo of a soluble form of CD6 was successfully employed as an anticancer strategy in mice (32). We observed enhancement of lymphocyte-mediated killing of cancer cells by a monoclonal antibody against CD318, a CD6 ligand, which may represent a combination of non-specific antibody-dependent cellular cytotoxicity and blockade of negative signals conveyed to lymphocytes from cancer cells arising from engagement of CD6 by CD318. Interruption of negative signals from cancer cells by UMCD6 does not, however, exclude the possibility that UMCD6 may also have a direct activating effect on T cells and NK cells.

NK cells are receiving increased attention recently as potential agents for cancer immunotherapy. Multiple structures on the NK cell surface can participate in activation of the NK cytotoxic program, while others have regulatory roles (33). The importance of CD6 in NK cell activation has hitherto not been appreciated, perhaps due to the absence of CD6 from mouse NK cells, in contrast to its expression on about 50% or more of human NK cells (7). Our data demonstrate that UMCD6 can alter the balance of expression of activating and inhibitory
receptors, and/or cytotoxic effector molecules on both NK and CD8+ lymphocytes. The changes observed thus far do not exclude potential roles of other alterations in surface structures and metabolic pathways that could be induced in cytotoxic lymphocyte populations by UMCD6.

Another anti-CD6 mAb has been used successfully in the treatment of psoriasis and thus far has an excellent safety record, pointing to the feasibility of testing anti-CD6 mAbs in the treatment of cancer as well as other autoimmune diseases (34,35). In assessing UMCD6 as a new candidate cancer immunotherapy agent, its consistently superior stimulation of cancer killing by lymphocytes in vitro, compared to either pembrolizumab or nivolumab, is notable, but will need confirmation in vivo, and using cells from patients with cancer, which may express higher levels of PD-1 than cells from healthy subjects. The distinct mechanism of action of UMCD6 points to the potential for additive or synergistic effects of combination strategies directed at both CD6 and targets of currently used checkpoint inhibitors.

MHC class I chain-related molecules (MICA and MICB) are well known ligands for the activating receptor NKG2D on NK and CD8+ T cells. Because MICA and MICB are highly expressed in a wide variety of tumor cells, targeting the CD6-CD318 axis with UMCD6 represents a novel and broadly applicable approach to cancer immunotherapy that boosts cancer cell killing by multiple downstream effects on cytotoxic lymphocyte gene expression and effector function. The data regarding UMCD6-induced changes in gene expression of key cytotoxic cell effector molecules and activating or inhibiting cell surface receptors reveals CD6 as a critical controlling molecule for the activation state and function of human cytotoxic lymphocytes.

Our experimental systems used lymphocytes that are not autologous to the cancer cell lines with which they were co-cultured. Nevertheless, our results are not explained by alloreactivity, for the following reasons. First, killing of cancer cells began far earlier in co-cultures than would be consistent with development of an allogeneic response. Second, far less killing occurred in the absence of UMCD6, or in the presence of various control monoclonal antibodies or IgG. Third, CD4+ lymphocytes, which are necessary for allosensitization, were not required
and are likely irrelevant to the observed killing. Finally, NK cell function is not based on alloreactivity.

Perhaps of greatest importance, however, is the dual effect of UMCD6 to both suppress autoimmune diseases through its effects on differentiation of effector CD4 cell subsets, while also activating the anti-cancer cytotoxic properties of CD8+ and NK cells. This dual effect creates the potential for an approach to cancer immunotherapy that would, distinct from currently available checkpoint inhibitors, suppress rather than instigate serious autoimmune diseases, thus overcoming the major current limitation to the success of checkpoint inhibition in the treatment of human cancer.

Materials and Methods

Cell lines and cell culture. The following human cancer cell lines were used in live cell imaging to assess immune cell killing of tumor cells: MDA-MB-231 (HTB-26™), triple-negative (i.e., ER−/PR−/HER2−) epithelial breast carcinoma; NCI-H460 (HTB-177™), large cell lung carcinoma; and LNCaP (HTB-1740™), androgen-sensitive prostate adenocarcinoma. Cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured in reduced riboflavin conditions using CMRL-1066 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% heat-inactivated FBS (HyClone, Chicago IL, USA), and 1% antibiotic-antimycotic solution (Gibco Life Technologies, Carlsbad, CA, USA). Cells were maintained at 37 °C in 5% CO2 and adherent cells were detached with trypsin (0.25%-EDTA, HyClone) for passaging and further culture. NK-92 cells were also purchased from ATCC and maintained in MEM-α containing 12.5% FBS, 12.5% horse serum (Gibco Life Technologies), 100 IU/ml IL-2 (R&D Systems), 0.2 mM inositol (Sigma-Aldrich), 0.02 mM folic acid (Sigma-Aldrich), and 0.1 mM mercaptoethanol (Gibco Life Technologies). Other cancer cell lines were screened for expression
of CD318 (Table I) and were grown in RPMI-1640 (HyClone) supplemented with 10% heat-inactivated FBS (HyClone) and 1% antibiotic-antimycotic solution (Gibco Life Technologies).

Antibodies. UMCD6, a mouse anti-human monoclonal antibody that targets the membrane distal domain 1 of CD6, was generated in our laboratory (36). UMCD6 was affinity purified and desalted by column chromatography using Protein G and dextran per manufacturer's instructions (Thermo Scientific). The 3a11 monoclonal antibody recognizes CD318 and was developed in our laboratory using IFN-γ treated HBL100 cells (16). 3a11 was used for immune killing assays and western blotting. Additionally, a second antibody against CD318 was purchased from Biolegend (clone CUB1) and was also used for flow cytometry analysis. Pembrolizumab and nivolumab (anti-PD-1 monoclonal antibodies) used for immune killing assays, were obtained from Merck, and Bristol-Myers Squibb respectively. Mouse anti-human von Willebrand factor (vWF) (37) and mouse anti-human Lymphocyte Function-Associated Antigen-1 (LFA-1; CD11a/CD18) were obtained from the Hybridoma Core Facility at the University of Michigan.

The following human antibodies were purchased commercially and were used for immunofluorescence staining: Alexa fluor 488 anti-human CD56 (Biolegend, clone 5.1H11), anti-CD3 (Biolegend, clone HIT3a), Alexa 488-conjugated goat anti-mouse IgG secondary antibody, (Jackson ImmunoResearch catalog # AB2338840), Alexa 488-conjugated donkey anti-mouse IgG secondary antibody (Thermo Fisher Scientific) and FITC-conjugated mouse IgG isotype control antibody (Biolegend. clone # HP6017).

The following antibodies were used for flow cytometry analysis. For surface staining: APC anti-human CD56 (Biolegend, clone 5.1H11), FITC anti-human CD56 (Biolegend, clone HCD56), APC/Cyanine7 anti-human CD8a (Biolegend, clone RPA-T8), PE/Cyanine7 anti-human CD3 (Biolegend, clone HIT3a), PE conjugated anti-human NKG2A (R&D Systems, FAB1059P), PerCP/Cyanine5.5 anti-human CD314 (NKG2D) (Biolegend, clone 1D11), FITC anti-human CD6 (Biolegend, clone BL-CD6), APC anti-human CD16 (Biolegend, clone 3G8). For intracellular
staining: FITC anti-human/mouse Granzyme B (Biolegend, clone GB11), PE anti-human/mouse Granzyme B (Biolegend, clone QA16A02), PerCP/Cy5.5 anti-human Perforin (Biolegend, clone B-D48), and APC anti-human Perforin (Biolegend, clone B-D48).

Flow Cytometry. MDA-MB-231, MDA-MB-361, MDA-MB-436, BT-20, BT-549, MCF7, T-47D, SK-BR-3 breast cancer cells; A375, A375-MA2, UM-MEL-1 melanoma cancer cells; PC3, LNCaP prostate cancer cells; and NCI-H460 lung cancer cells were used to determine CD318 expression by flow cytometry. Briefly, cells were incubated with Fc receptor blocking solution (Biolegend, San Diego, CA, USA) and stained with purified anti-human CD318 antibody (Biolegend, clone CUB1) in FACS buffer (PBS + 2% FBS + 2mM EDTA) for 30 minutes on ice. Cells were subsequently washed in 1X PBS and stained using Alexa 488-conjugated donkey anti-mouse IgG secondary antibodies (Thermo Fisher Scientific) for 30 minutes on ice. Viability was assessed by staining with Zombie Violet and cells were analyzed by flow cytometry at the University of Michigan Flow Cytometry Core on a BD Fortessa (Becton Dickinson, San Jose, CA, USA). Analysis of flow cytometry data was performed using FlowJo software (Treestar, Ashland, OR, USA).

To determine the expression of NKG2A and NKG2D, peripheral blood mononuclear cells were incubated with Fc receptor blocking solution for 10 minutes at room temperature followed by incubation with fluorescent antibodies against NKG2A (R&D Systems, FAB105P-025), NKG2D (Biolegend, 320817), CD56 (Biolegend, 318303), CD8 (Biolegend, 301016), CD3 (Biolegend, 300311), CD16 (Biolegend, 302011) and CD6 for 30 minutes on ice. For the intracellular staining of Granzyme-B and perforin, cells were first stained for anti-CD56, anti-CD3, anti-CD8 and then fixed and permeabilized with fix/perm solution (Invitrogen, 00-833-56) for 45 minutes at room temperature. Cells were subsequently incubated with either anti-Granzyme-B or anti-Perforin for 30 minutes at room temperature. Finally, cells were resuspended in 200 µl of FluoroFix™ buffer (Biolegend) and analyzed by flow cytometry on a BD FACSCanto™ II at the University of Michigan.
**Western Blotting.** Cell lysates were obtained from breast cancer cell lines MDA-MB-231 and MCF7 before and after stimulation with 1,000 U/mL human IFN-γ. Equal amounts of protein (15µg per lane) were separated by Tris-Glycine SDS-PAGE and electro-blotted onto nitrocellulose membranes. CD318 proteins were detected using anti-CD318 mAb 3a11 at 10µg/mL, while β-actin (Sigma Aldrich) was used as loading control. Bands were imaged on an Amersham Imager 600RGB (GE Healthcare) and quantification was performed using GelQuant.NET (BiochemLab Solutions).

**RNA extraction and quantitative real-time RT-PCR analysis.** 1x10⁶ NK-92 cells were treated with 10µg/mL of either UMCD6 or IgG and collected after 4 hours. Total RNA from treated NK-92 cells was extracted using Direct-zol RNA MiniPrep (Zymo Research, Irvine, CA), and cDNA synthesis was carried out using verso cDNA Synthesis Kit (Thermo Fisher Scientific). The following primers were used for RT-PCR: NKG2A F: 5′-ACTCATTGCTGGTACCCTGGG-3′, NKG2A R: 5′-GAGGACAAGGCTGTGCTGAAG, NKG2D F: 5′-TTCAACACGATGGCAAAAGC-3′ NKG2D R: 5′-CTA CAG CGA TGA AGC AGC AGA-3′, Perforin F: 5′-GCTGGACGTGACTCCTAAGC-3′, Perforin R: 5′-GATGAAGTGGGTGCCGTAGT-3′, Granzyme-B F: 5′-GCAGCCTTCTGAGAAGATG-3′, Granzyme-B R: 5′-CCGCACCTCTTCAGAGACTT-3′.

The quantification of the mRNA expression was performed using the primers above and SYBR Green PCR Master Mix Reagent (Thermo Fisher Scientific) on a Viia V.7 Real-Time PCR System (Applied Biosystems). Triplicate measurements were performed for each sample. Real abundance for each gene was calculated using the ΔΔCT method and β-actin was used as an internal standard for normalization.

**ELISA of soluble CD318.** Cell supernatants from MCF7 and MDA-MB-231 breast cancer cell lines were collected for the measurement of soluble CD318 by an ELISA kit (R&D Systems) following the manufacturer’s protocol.
**Lentivirus transduction.** To develop cell lines with nuclear fluorescence for live imaging, lentiviral stocks were developed by the University of Michigan Vector Core using an mKate2 2X nuclear localization fusion construct. Tumorigenic MDA-MB-231, NCI-H460 and LNCaP cells were seeded at $3 \times 10^5$ cells/well on 6-well plates (Corning, NY, USA) overnight. The following day, cells were washed in PBS and cell media was replenished with 1.35mL of fresh media, 150µl of 10X lentiviral stock supernatant (~6 MOI), and 4µg/mL of polybrene (Sigma-Aldrich, St. Louis, MO, USA). Plates were incubated at 37°C with 5% CO₂ for 24 hours. Subsequently, mKate2-transduced cells were washed in PBS and expanded in culture until optimal confluency.

To isolate individual clones of transduced cells, fluorescent MDA-MB-231, NCI-H460 and LNCaP cells were singly sorted into individual wells of a 96 well plate (Corning) at the University of Michigan Flow Cytometry Core using a FACS Synergy Head #1 cell sorter (Sony Biotechnology, San Jose, CA, USA). The viability marker Zombie Violet (BioLegend) was used to exclude dead cells. The cells sorted were negative for Zombie Violet (450/50 (405)) and in the top 5% of mKate fluorescence intensity (615/30(561)).

To monitor tumor growth by bioluminescent imaging in vivo, MDA-MB-231 breast cancer cells were transduced with a luciferase lentivirus reporter regulated by the CMV promoter (purchased from the University of Michigan Vector Core). Transduction was carried out by centrifuging $2 \times 10^6$ cells in 1mL of media (1,000xg for 2 hours) with addition of 8µg/mg of polybrene and 1mL of 10x luciferase virus (~6 MOI). Culture media was replaced with fresh, warm media after 18 hours and luciferase expression was analyzed 5 days later using a Dual-Luciferase® Reporter Assay System (Promega, Madison, WI, USA) and bioluminescent imaging.

**Isolation of peripheral blood mononuclear cells (PBMCs).** Venous blood from healthy volunteers was collected in sterile anticoagulant vacuum tubes (BD Vacutainer sodium heparin). PBMCs were isolated using dextran sedimentation and Ficoll-Paque density-gradient separation (GE Healthcare, Chicago, IL, USA). The gradient was then centrifuged at 400g for 15 min and the
buffy coat was collected and washed in PBS. Isolated PBMCs were re-suspended at $1 \times 10^7$ cells/mL in RPMI-1640 culture medium supplemented with 10% FBS. Viability was measured by trypan blue dye exclusion assay (Thermo Fisher Scientific). PBMCs were used directly for immune cell killing assays or were enriched for specific subpopulations. NK and CD8+ cells were purified from PBMCs using the EasySep® Human NK Cell Isolation Kit and EasySep® Human CD8 Positive Selection Kit respectively (STEMCELL Technologies, Vancouver, Canada).

**Cancer cell killing assays.** Nuclear fluorescent MDA-MB-231 and LNCaP tumor cells were seeded in 96-well plates (Corning) at a density of $2 \times 10^4$ cells per well and grown overnight. NCI-H460 tumor cells were plated at $2 \times 10^3$ cells per well and also maintained overnight. On the day of the assay, PBMCs were isolated from healthy volunteers as previously described, and stocks of $1 \times 10^6$ PBMCs/mL were separately incubated with 10µg/mL of either UMCD6 or IgG isotype control antibodies directed against von Willebrand Factor (vWF) or anti-LFA-1 for 1 hour at 37°C. Subsequently, 50µl of the PBMC/antibody solution (50,000 PBMCs/well) and 50µl of caspase-3/7 reagent at 5µM (Essen Bioscience, Ann Arbor, Michigan) were added to each well.

Cells were imaged at tenfold magnification in an IncuCyte® S3 Live Cell Analysis System (Sartorius) at 37°C with 5% CO₂. Images were acquired every 30 minutes or 1 hour for 5 to 7 days, two to four images per well. Data were analyzed using IncuCyte analysis software to detect and quantify the number of green (apoptotic) cells per image. A filter threshold of 100 µm² was established to remove PBMC death events and other green fluorescent aberrations. The number of red events (survival of tumor cells) was calculated by counting red fluorescent mKate2 expressing nuclei. Data were plotted using GraphPad Prism software.

We also compared the effectiveness of UMCD6 versus PD-1 inhibitors pembrolizumab and nivolumab. Similar to previous immune cell killing assays, MDA-MB-231 and NCI-H460 cell lines were seeded in 96-well plates at $2 \times 10^4$ cells/well and $2 \times 10^3$ cells/well respectively. $1 \times 10^6$/mL PBMCs, NK, and CD8+ cells were isolated and incubated in separate tubes with 10µg/mL of either
UMCD6, pembrolizumab, nivolumab or an IgG isotype control antibody for 1 hour at 37°C. 50µl/well of the immune cells/antibody mixtures were layered over the MDA-MB-231 and NCI-H460 cells. 50µl of caspase-3/7 reagent (5µM) were also added to each cancer well. Cells were imaged in IncuCyte® S3 Live Cell Analysis System as previously described.

Subcutaneous xenograft study. To assess the effects of UMCD6 in vivo, severe combined immunodeficient (SCID) beige mice (Charles River, Wilmington, MA, USA) were injected subcutaneously with 5×10⁶ luciferase-infected MDA-MB-231 cells. Mice were anesthetized through the intraperitoneal route with a mixture of ketamine (80-120 mg/kg) and xylazine (5-10 mg/kg), and tumor cells were injected into the right flank of each mouse. Tumor growth was monitored by bioluminescence imaging. 26 days after cell implantation, when tumors had reached volumes of at least 100mm³, 10 mice were randomly allocated to receive an intravenous injection of 1.2×10⁷ PBMCs via the tail vein, while the 3 other mice (control group) received PBS.

The following day, mice that had received PBMCs were divided into two groups, selected such that the range of tumor sizes was equal between the groups: 5 mice received a single dose of UMCD6 (400µg/mouse) and 5 mice instead received an IgG control antibody (400µg/mouse) intraperitoneally. Tumor growth was monitored every other day by bioluminescence imaging. To assess tumor volume via bioluminescence imaging, mice were intraperitoneally injected with 100µl of sterile D-luciferin at 15mg/mL (Gold Biotechnology, St Louis, Missouri, USA) and anesthetized with 2% isoflurane. Mice were then imaged with a Xenogen IVIS 200 bioluminescence camera following D-luciferin administration and images were captured after one minute of exposure and then quantified using Living Image 2.60.1 software. All images were normalized to the same scale and exposure time.

Internalization of UMCD6. UMCD6 was directly labeled with cyanine 3 (Cy3) and successful antibody labeling was verified by flow cytometry. PBMCs from a healthy donor were stained with
Cy3-conjugated UMCD6 at 4°C for 30 minutes. A Cy3-labeled CD45 antibody (Biolegend, clone 30F11) was used as control. Green fluorescent images were acquired through an IncuCyte® S3 Live Cell Analysis System at 37°C every hour for 5 days and internalization was measured by loss of green expression at the cell surface.

**Immunofluorescence Histochemistry.** Xenograft tumors derived from MDA-MB-231 cells were dissected for histological examination. Tumors were harvested and placed in 4% PFA for at least 48 hours. Subsequently, tissues were embedded in ornithine carbamyl transferase (OCT) for cryosectioning at 8µm using a Leica CM1950 cryostat (Leica, Wetzlar, Germany).

For immunofluorescence staining, slides were fixed with 4% paraformaldehyde and blocked for nonspecific binding using 10% goat serum and 5% FBS in PBS (Millipore, Temecula, CA) for 2 hours at room temperature. Goat anti-human CD56 (Biolegend, clone 5.1H11) or goat anti-human CD3 (Biolegend, clone HIT3a) were incubated at 1:100 dilutions overnight at 4°C. After primary antibody incubation and washing, secondary goat anti-mouse IgG coupled to Cy3 antibody (Jackson ImmunoResearch laboratories Inc., West Grove, PA, USA) was added to each slide for 1 hour at room temperature. To preserve fluorescence, samples were mounted using a DAPI solution containing Prolong™ Gold antifade and mounting medium (Invitrogen). Negative controls included isotype control antibodies. Fluorescence images were taken using an Olympus BX51 microscope equipped with a 40X lens objective (Olympus America Inc., NY, USA). Images were captured with an Olympus DP-6 digital camera and processed with Adobe Photoshop 2020.

**Statistical Analysis.** Statistical analyses for the cancer killing assays were performed using Graph Pad software (Graph Pad Inc., San Diego, CA). Data are shown as mean ± standard error of the mean (SEM) and statistical significance between two groups was determined by unpaired Student’s t-test and *p<0.05 was considered statistically significant. Total expression of NK receptors was calculated for each extracellular and intracellular marker by multiplying the mean
fluorescence intensity of the positive cells by the percentage of positive cells. Data are presented as the ratio UMCD6-treated over IgG control at 0, 24, 48 and 72 hours. A paired 2-tailed t-test was used to determine statistical significance, *p<0.05, n=6.

**Study approval.** Animal experiments were done in accordance with ethical guidelines and approved by the Animal Care and Use Committee at the University of Michigan (Immunopathogenesis of Malignancies and Chronic Inflammatory Disorders (PRO00008344)). PBMCs from healthy volunteers were isolated in our lab following appropriate guidelines approved by the University of Michigan (Unique Surface Structures of Synovial Cells IRBMED 1988-0305 (HUM00043197)).

**Author contributions**

JHR and DAF designed this study. MGR, JHR and DAF contributed to drafting of the manuscript. MGR, MAA and PLC performed in vivo experiments in mice. MGR, KSA, SMR, DPW, PR, RJG, and MEL performed and analyzed the cancer cell killing assays. MGR, PR, RJG and MEL conducted immunohistochemical staining. MGR and QW designed, performed, and analyzed the NK and CD8 flow cytometry panels. TML provided mKate2 2X nuclear localization fusion construct. VGK provided and analyzed the Affymetric data. PST, YMD, NGS and FL helped with drafting of the manuscript and conceptual framework of this study.

**Acknowledgements**

This study was supported by funds from the National Institute of Health (NIH) Autoimmunity Center of Excellence and NIH Training Grant T32AR007080, with additional funds acquired from the University of Michigan Rogel Cancer Center, the Michigan Translational Research & Commercialization program and the Frederick G L Huetwell and William D Robinson Professorship in Rheumatology at the University of Michigan.
References


Figure 1. Expression of CD318 on multiple cancer cell lines. Upper panel: Flow cytometry revealed robust expression of CD318 on the breast cancer lines BT-549, T-47D, MDA-MB-361, BT-20, MDA-MB-436, MDA-MB-231 and SK-BR-3, the prostate cancer lines PC3 and LNCaP, the melanoma cell lines A375 and A375-MA2 and the non-small cell lung cancer (NSCLC) line NCI-H460. Tumor lines with low expression of CD318 included MCF7 (breast), UM-MEL-1 (melanoma), and HS587 (lung) – not pictured above. Middle left panel: FACs analysis was confirmed by immunoblotting of tumor cell lysates from MDA-MB-231 and MCF7 HBCCs. IFN-γ had a negligible effect on CD318 expression on HBCCs, distinct from the previously observed induction of CD318 by IFN-γ on cultured synovial fibroblasts. Middle and lower right panels: MDA-MB-231 and MCF7 human breast cancer cells (HBCs) were plated in a 96-well plate at 20,000 cells per well, followed by addition of 50,000 CFSE-labeled T cells (n=64). Adhesion was measured after 1 hour at 37°C as CFSE green fluorescence using a BioTek Synergy Plate Reader. More lymphocytes bound to the CD318-positive MDA-MB-231 cells than to the CD318-negative MCF7 cells. Lower left panel: Soluble CD318 is shed from CD318+ cancer cells. ELISA for soluble CD318 in culture supernatants of CD318 negative MCF7 cells and CD318 positive MDA cells shows that HBCCs that express CD318 can also shed sCD318 into cell culture supernatants at concentrations previously shown to induce lymphocyte chemotaxis.
Figure 2. UMCD6 antibody enhances cancer cell killing by PBMCs. Tumor cells were co-cultured and imaged using an Incucyte system that recorded tumor cell number (right panels, red fluorescence with y-axis log2) and cell death (left panels, green fluorescence, caspase sensitive with y-axis linear). Upper panels: CD318-expressing MDA-MB-231 cancer cells were plated in a 96-well plate with a seeding density of 20,000 cells per well. 50,000 PBMCs were added to the LNCaP cell cultures at 4 hours. Before addition to the co-cultures, PBMCs were incubated for one hour at 37°C with either UMCD6 or mouse IgG control antibodies. MDA HBCCs and LNCaPs displayed profound enhancement of clumping and caspase expression in co-cultures in which PBMCs were exposed to UMCD6 (left panels). MDA and LNCaP cells also displayed inhibited growth in the wells containing UMCD6-treated PBMCs (right panels). Statistical significance (*p<0.05) was initially achieved for MDA-MB-231 between the UMCD6 and anti-LFA-1 IgG treated co-cultures at 39 hours (green caspase cell death) and 51 hours (red survival). Similarly, differences in LNCaP cell death became significant at 8.5 hours (left panel) and at 43.5 hours for survival (right panel) between UMCD6 and anti-vWF IgG co-cultures.
Figure 3. UMCD6 antibody enhances non-small cell lung cancer (NSCLC) cell killing by PBMCs. Upper right panel: Nuclear localized mKate2-transduced NCI-H460 cells were plated in a 96-well plate at 2,000 cells per well. PBMCs (35,000) were added (n=24 wells for each condition) at 22 hours (indicated by arrow in chart). Before addition to the co-cultures, PBMCs were incubated for an hour with either UMCD6 (mouse anti-human CD6) or mouse anti-human vWF, an IgG control antibody that did not bind to either PBMC or the tumor cells or pembrolizumab or nivolumab, all at 10 micrograms/mL. Tumor cell killing was measured in an IncuCyte cell imaging device as the number of NCI-H460 cells in each well expressing nuclear caspase (green fluorescence). NCI-H460 cells in cultures with UMCD6 showed profound clumping and caspase expression after 101.5 hours (scan no. 203) compared to the IgG’ control or anti-PD1 treated co-cultures (data expressed as mean ± sem; green fluorescence, caspase sensitive with y-axis linear). Upper right panel: Tumor cell survival was measured as the number of red fluorescing tumor cells remaining in culture (right panels, red fluorescence tumor cell survival with y-axis linear). The number of surviving tumor cells was significantly higher in the IgG, pembrolizumab and nivolumab groups compared to the wells containing PBMCs that had been pre-incubated with UMCD6 (red line in chart).

Lower panel: Multivariate survival analysis in patients with lung adenocarcinoma stratified according to cancer cell expression of the CD6 ligands CD318 and CD166/ALCAM. Multivariate analysis was done by including stage, gender and smoking history of patients (n=387) (Cox Regression). Overall survival analysis revealed increased expression of CD318 strongly correlated with poor patient survival. However, CD166/ALCAM expression correlated with a better prognosis/longer patient survival.
Figure 4. Effect of UMCD6 on breast cancer cell killing by PBMCs compared to effects of checkpoint inhibitor immune therapeutics directed at the PD1/PDL1 axis. Upper panel: MDA-MB-231 tumor cells were plated in a 96-well plate at 20,000 cells/well. 50,000 PBMCs were added to the MDA-MB-231 cell cultures at 8 hours. Before addition to the co-cultures PBMCs were incubated for one hour at 37°C with either UMCD6, vWF-IgG, or with the same concentration of pembrolizumab or nivolumab, all at 10µg/mL. Cancer cell killing was measured by the number of breast cancer cells present in each well (red fluorescence tumor cell survival with y-axis log₂) and cell death (green fluorescence, caspase sensitive with y-axis linear). Peak killing of cancer cells occurred around 61 hours at which time MDA-MB-231 cells displayed profound caspase expression compared to the anti-vWF treated wells (left panel: *p=1.712x10⁻¹⁴ at 61 hours). Statistical significance for caspase expression was initially achieved for MDA-MB-231 cell death at 31 hours for UMCD6 vs. pembrolizumab and nivolumab - and at 30 hours for UMCD6 vs control IgG. MDA-MB-231 cells also showed inhibited growth and survival when exposed to UMCD6-treated PBMC compared to the IgG control group from the beginning of the experiment that persisted and increased through 143 hours (right panel: UMCD6 vs anti-vWF *p=5.757x10⁻⁹, UMCD6 vs pembrolizumab *p=7.260x10⁻⁸, UMCD6 vs nivolumab *p=7.186x10⁻¹⁰ at the final time point). Lower panel: Single images of tumor cells in co-culture with PBMCs and various antibody treatments. Hour 30 shows a co-culture of PBMCs (small round black cells) with dying tumor cells expressing caspase in the wells treated with UMCD6 (arrow). By 61 hours, plate wells treated with UMCD6 showed significantly more tumor cells with pronounced caspase expression that contained fewer tumor cells compared to co-cultures treated with pembrolizumab, nivolumab, anti-vWF or caspase reagent control culture.
Figure 5. CD6+ NK cells treated with UMCD6 are highly effective at killing MDA-MB-231 tumor cells. Upper panel: Tumor cell killing assays were set up using 50,000 immune cells and 20,000 MDA-MB-231 HBCCs and antibodies at 10μg/mL. PBMCs pre-incubated with UMCD6 killed tumor cells much more effectively than PBMCs pre-incubated with IgG control antibody, pembrolizumab or nivolumab (right panels, red fluorescence tumor cell survival with y-axis log2) and cell death (left panels, green fluorescence, caspase sensitive with y-axis linear). Middle panel: Isolated CD8+ cells showed enhanced killing and lower tumor cell survival in cocultures with UMCD6, compared to the other antibodies. Lower panel: Only UMCD6 induced tumor cell killing by purified NK cells.
Figure 6. UMCD6 reduces tumor size in SCID beige mice. Human breast cancer cells (MDA $5 \times 10^6$ cells) were inoculated s.c. in the ventral aspect of the abdomen of female SCID beige mice. Once tumors reached a size of about $100 \text{mm}^3$ some mice were administered $12 \times 10^6$ human PBMCs by tail vein (considered day 0). The next day mice that had received PBMCs were injected i.p. with either 0.4 mg control IgG or UMCD6. Mice not administered PBMCs received no antibodies (untreated). Tumors were measured by IVIS (in vivo imaging) thereafter. The effect of UMCD6 on tumor volume can be seen at day 4 and 7 after UMCD6 administration (*p<0.05) compared to both the IgG and no-treatment groups. Data represent mean of 3-5 animals ± sem. 2-tailed t-test at day 7: UMCD6 vs IgG, p=0.0052; UMCD6 vs untreated, p=0.0109. 2-tailed t-test at day 4: UMCD6 vs IgG, p=0.0038; UMCD6 vs untreated, p=0.0177.
Figure 7. UMCD6 induces up-regulation of NKG2D on NK and CD8+ T cells. Upper panels: NK-92 cells were incubated with 10 µg/ml of IgG or UMCD6 and harvested after 4 hours. Real-time PCR revealed significantly higher levels of mRNA for the activating receptor NKG2D, as well as perforin and granzyme-b upon incubation with UMCD6, while mRNA for the inhibitory receptor NKG2A was down-regulated. Data expressed as mean +/- SD and *p<0.05. Lower panels: representative flow cytometry plots showing NKG2D-positive NK and CD8+ T cells. PBMCs from 6 subjects (n=6) were isolated as described in materials and methods and subsequently cultured with 10µg/ml of IgG or UMCD6. Increase of cell surface expression of NKG2D was evident 72 hours after treatment with UMCD6 on NK cells (gated on CD3-CD56+ cells) (middle panel) and CD8+ T cells (gated on CD3+CD8+ cells) (lower panel).
Supplementary figure 1. NCI-H460 (NSCLC) cells express CD318. Upper panel: FACs analysis on NCI-H460 lung cancer cells revealed that CD318 is expressed on nearly all of the tumor cells (96.6%). Cell surface CD318 expression was evaluated using a mouse anti-human CD318 antibody (Miltenyi Biotec) at 1:100 dilution with 5x10^5 cells in FACs buffer. Representative negative control histogram using NCI-H460 NSCLC cells shows 0.062% positivity. FcR Blocking Reagent was added to all cells to block non-specific antibody binding to cancer cells (Miltenyi Biotec). Similar background fluorescence was obtained using IgG control antibody for all cell lines evaluated for CD318 expression. Lower panels: MDA, but not MCF7 HBCCs, express CD318. FACs analysis on MDA (lower left panel) and MCF7 (lower right panel) HBCCs revealed that CD318 is expressed on nearly all of the MDA cells but on 10% of MCF7 cells. The addition of IFN-γ (1000 U/mL) did not significantly alter MDA or MCF7 CD318 expression in vitro. Notably, CD166 (ALCAM) an alternative CD6 ligand, was highly expressed on MDA-231 (NS: 100%; IFN-γ: 99.7%) and MCF7 (NS: 95.7%; IFN-γ: 91.6%) HBCCs regardless of stimulation with IFN-γ. NS is no stimulus.
Supplemental Figure S2. UMCD6 enhances LNCaP prostate cancer cell killing in vitro by human PBMCs. In the absence of mAbs and/or PBMCs (right column – untreated wells), LNCAP proliferation was unimpeded (fluorescent red cells). LNCAP prostate cancer cells co-cultured with UMCD6-treated PBMCs displayed profound clumping and caspase expression (fluorescent green dye) at 72 hours and were almost completely eliminated by 165 hours (see arrows). In the presence of control antibody and PBMCs modest killing of LNCaP cells was observed, but viable cancer cells persisted. The experiment was performed using the IncuCyte imaging device.
Supplemental Figure S3. Time course of UMCD6 mediated killing of NSCLC cells (NCI-H460) by human PBMCs. CD318 expressing NCI-H460 cells were plated in a 96-well plate with a seeding density of 2,000 cells per well. Non-activated PBMCs (35,000) were added to the tumor cells at about 22 hours. Before addition to the co-cultures PBMCs were incubated for an hour with either UMCD6 (mouse anti-human CD6) or mouse anti-human vWF (a non-specific IgG control antibody) or nivolumab or pembrolizumab (10µg/mL). Tumor cell killing was measured in an IncuCyte cell imaging device by evaluating the number of NCI-H460 cells present in each well expressing nuclear caspase (green fluorescence). NCI-H460 cells in co-cultures with UMCD6 showed profound clumping and caspase expression after 101.5 hours (see arrow) compared co-cultures with other treatments. Notable loss of red fluorescing NSCLC tumor cells – indicating inhibited growth and cell survival can be seen starting at about 3 days in co-cultures treated with UMCD6.
Supplemental Figure S4. Internalization of UMCD6 by lymphocytes. UMCD6 binding to CD6 initiates CD6 capping and complete internalization from the cell surface within 6 hours (see arrow). Human peripheral blood lymphocytes were incubated with either Cy3-labeled UMCD6 or anti-CD45 at 4°C for 30 minutes and fluorescent images were taken at 40X magnification at 1, 2, 4 and 6 hours. Upper panel: fluorescent green images show capping of CD6 on most cells at 1 hour, followed by internalization of UMCD6 with loss of green fluorescence on the cell surface. Lower panel: CD6 and CD45 surface expression on PBMCs were analyzed by the green object count per image through the IncuCyte imaging system, compared to the count at time 1 hour, which was set at 100%. The graph shows that the percentage of CD6+ fluorescent cells decreased rapidly to 0% over 6 hours, while CD45 surface staining remained nearly constant (90-95%) for 5 days (n=8).
Supplemental Figure S5. Accumulation of lymphocytes in MDA-MB-231 tumors xenotransplanted into SCID beige mice following infusion of human PBMCs and UMCD6. Tumors were removed at day 36 after injection of tumor cells into the flanks of SCID beige mice, day 10 after infusion of 12x10^6 PBMCs, and day 9 after intraperitoneal injection of 0.4 mg UMCD6 or control IgG. Tumors were cryosectioned and immunostained for CD56 and CD3. Upper panel: Tumor tissues immunostained for CD56 (human NK cell marker) or CD3 (human lymphocyte marker) from mice administered UMCD6 showed activated NK cells that were associated with areas of decreased density of tumor cells (40X). CD3+ lymphocyte staining revealed results similar to the NK cell staining. DAPI stain is shown in fluorescent blue. Lower panel: Numbers of CD56+ NK cells, CD3+ T lymphocytes and tumor cells were evaluated by counting the numbers of green or red fluorescent cells/hpf. MDA cells were fluorescent red due to expression of a transfected RFP. The numbers of CD56+ and CD3+ cells/hpf were significantly higher in the UMCD6-treated mice (CD56: 1 section/tumor from n=5 mice for UMCD6 and IgG, and 1 section/tumor from n=3 mice for untreated) whereas the number of tumor cells was significantly decreased compared to mice that received either control IgG + PBMCs or no treatment (1 section/tumor from n=5 mice for UMCD6 and IgG, and 1 section/tumor from n=3 mice for untreated).
Supplemental Figure S6. MDA-MB-231 xenografts are reduced with UMCD6 treatment. Tumor cell density in MDA-MB-231 xenografts are shown. Upper panel: representative images of endogenous red fluorescent tumor cells in each xenografted tumor harvested 10 days after PBMC infusion. Fewer mKate2-transduced MDA-MB-231 cells are seen at 40x magnification in mice receiving UMCD6 compared to mice receiving IgG control antibody or in untreated mice. Notable differences in tumor sizes among the different groups can be seen at 4X. UMCD6 treated mice exhibited tumors with large gaps in the tumor microenvironment that were not observed in the IgG control and untreated mice (see arrows).
Figure S7. Effect of UMCD6 on the expression of NKG2A, NKG2D, Granzyme-b and perforin by NK and CD8+ T cells. Expression levels of the inhibitory receptor NKG2A, activating receptor NKG2D, cytotoxic serine protease Granzyme-b, and pore-forming protein perforin were studied by flow cytometry. Total expression was calculated for each extracellular and intracellular marker by multiplying the mean fluorescence intensity of the positive cells by the percentage of positive cells. Data are presented as the ratio UMCD6-treated over IgG control at 0, 24, 48 and 72 hours. A paired t-test was used to determine statistical significance, *p<0.05, n=6. Upper panels: upon activation with UMCD6, NK cells upregulated the expression of NKG2D by 48 and 72 hours, whereas the expression of NKG2A was downregulated by 24 and 72 hours (p<0.05). Granzyme-b was upregulated by 48 hours (*p<0.05) and perforin expression was upregulated at 48 and 72 hours (p<0.05). Lower panels: UMCD6 effect on CD8+ T cells reveals a statistically significant increase in the expression of perforin (p<0.05) at 72 hours (n=6).
### Table I

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Cell state</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>BT-549</td>
<td>ductal carcinoma</td>
<td>ATCC® HTB-122™</td>
</tr>
<tr>
<td>T47D</td>
<td>ductal carcinoma</td>
<td>ATCC® HTB-133™</td>
</tr>
<tr>
<td>MDA-MB-361</td>
<td>breast adenocarcinoma</td>
<td>ATCC® HTB-27™</td>
</tr>
<tr>
<td>BT-20</td>
<td>breast adenocarcinoma</td>
<td>ATCC® HTB-19™</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>breast adenocarcinoma</td>
<td>ATCC® HTB-26™</td>
</tr>
<tr>
<td>MDA-MB-436</td>
<td>breast adenocarcinoma</td>
<td>ATCC® HTB-130™</td>
</tr>
<tr>
<td>SK-BR-3</td>
<td>breast adenocarcinoma</td>
<td>ATCC® HTB-30™</td>
</tr>
<tr>
<td>MCF</td>
<td>breast adenocarcinoma</td>
<td>ATCC® HTB-22™</td>
</tr>
<tr>
<td>PC3</td>
<td>prostate adenocarcinoma</td>
<td>ATCC® CRL-1435™</td>
</tr>
<tr>
<td>LNCaP</td>
<td>prostate carcinoma</td>
<td>ATCC® HTB-1740™</td>
</tr>
<tr>
<td>A375</td>
<td>malignant melanoma</td>
<td>ATCC® CRL-1619™</td>
</tr>
<tr>
<td>A375-MA2</td>
<td>malignant melanoma</td>
<td>ATCC® CRL-3223™</td>
</tr>
<tr>
<td>UM-MEL-1</td>
<td>metastatic melanoma</td>
<td>Dr. Sofia Merajver (University of Michigan, Ann Arbor)</td>
</tr>
<tr>
<td>NCI-H460</td>
<td>large cell lung carcinoma</td>
<td>ATCC® HTB-177™</td>
</tr>
<tr>
<td>HS587</td>
<td>lung carcinoma</td>
<td>ATCC® CRL-7352™</td>
</tr>
</tbody>
</table>